

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Post COVID recurrent fever in children with polymorphisms in the innate immunity regulator, pyrin; *MEFV* gene

Levi Keller, MD^a, and Nathan Rabinovitch, MD, MPH^b

Clinical Implications

Children with persistent recurrent fevers after coronavirus disease 2019 (COVID-19) infection should be tested for polymorphisms in the innate immunity regulator, pyrin; gene *MEFV*. These children improve with daily colchicine therapy.

Emerging after the global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), reports of prolonged symptoms after coronavirus disease 2019 (COVID-19) illnesses were reported. Now known as long-COVID or post-COVID by the U.S. Centers for Disease Control and Prevention, they are defined as persistent symptoms lasting longer than 12 weeks after the initial illness. A meta-analysis of pediatric patients observed 25% of pediatric patients experiencing long-COVID symptoms. Approximately 2% of these patients experienced recurrent fever.¹ We present 2 adolescent males with a pathogenic heterozygous mutation in the innate immunity regulator, pyrin: *MEFV* gene (p. A744S) in the setting of recurrent fever, fatigue, and brain fog after SARS-CoV-2 infection. Treatment with colchicine significantly improved these symptoms.

The first patient was a 13-year-old unimmunized male who experienced COVID-19 illness in January 2022. Prior to his illness, his mother reported intermittent flushing with a maximum temperature of (99°F [37.2°C]) occurring every 2 to 3 weeks. When he was evaluated in March 2022, he was experiencing recurrent fever (101°F [38.3°C]), arthralgias, fatigue, and brain fog that coincided with fevers. Symptoms would last for 1 to 2 days and recur every 4 to 5 days. Pharyngitis, aphthous ulcers, and adenopathy were absent. His medical history was notable for attention deficit disorder, and his family history was positive for atopy and migraine headaches. His family's heritage was European. No other family members endorsed recurrent fevers despite having also contracted COVID-19.

The second patient was a 10-year-old, fully immunized, male who also had acute COVID-19 in January 2022. He was evaluated in June 2022 and had symptoms of fevers (101°F [38.3°C]), brain fog, fatigue, pharyngitis, and disequilibrium occurring every 3 to 4 days. Aphthous ulcers or adenopathy was not reported. His mother reported a history prior to COVID-19 infection of recurrent fevers (101°F [38.3°C]) every 6 to 8 days. He had previously been evaluated for recurrent fevers, but no infectious, malignant, or autoimmune trigger had been identified. The child's family was of European (Spanish and Irish) heritage with a family history positive for autoimmunity and atopic disease.

Both patients underwent laboratory analysis for inflammatory markers and cytokine analysis (Table I) at the time they were

TABLE I. Cytokine and inflammatory marker analysis*

Cytokine	Normal Range	Patient 1	Patient 2
TNF-α	0-22.30 pg/mL	7.65	6.37
IFN-γ	0-24.10 pg/mL	<3.20	<3.20
IL-10	0-19.00 pg/mL	6.55	<3.20
IL-6	0-11.90 pg/mL	4.44	<3.20
IL-2	0-60.80 pg/mL	<3.20	<3.20
IL-4	0-4.10 pg/mL	<3.20	<3.20
IL-5	0-4.10 pg/mL	<3.20	<3.20
IL-12	0-8.40 pg/mL	<3.20	<3.20
Patient 1	ESR	Ferritin	Temperature (°C)
February 15, 2022	8	26.8	36.2
September 8, 2022	8	28	36.5
Patient 2	ESR	Ferritin	Temperature (°C)
March 11, 2022	29	94	37.9
May 23, 2022	21.9	103	37.2


ESR, Erythrocyte sedimentation rate; *IFN-* γ , interferon gamma; *IL*, interleukin; *TNF-* α , tumor necrosis factor alpha.

*Values were obtained when the patients were afebrile.

afebrile. Erythrocyte sedimentation rate and ferritin levels were elevated in the second patient only and plasma T-helper (Th1 and Th2) cytokines (by Luminex) were all within normal limits. These patient's recurrent fever history prompted genetic testing (Invitae autoinflammatory panel) that identified a heterozygous, pathogenic mutation in the MEFV gene (p. A744S) that encodes pyrin; a protein that regulates inflammasome activation in response to infection. In both patients, this variant was inherited from the mother. The second patient's brother (age 14 years) carried the same mutation but was not symptomatic despite experiencing COVID-19 concurrently (Figure 1). Colchicine therapy (0.6 mg twice daily) was initiated for both patients resulting in near-immediate resolution of fevers and improvement in other symptoms. They were also evaluated by a pediatric rheumatologist who agreed with a trial of colchicine and suggested familial Mediterranean fever (FMF) in the first patient and PFAPA (periodic fever, aphthous stomatitis, pharyngitis, and adenitis) in the second, although both had atypical presentations.

Periodic fever syndromes including PFAPA and FMF usually begin in early childhood with PFAPA typically remitting in childhood and FMF persisting lifelong. The PFAPA is the most common periodic fever syndrome in children and is polygenetic. One study found the heterozygote A744S MEFV variant in 10% of patients with PFAPA.² The FMF is a monogenetic disease characterized by episodes of pleuritis, arthritis, gastrointestinal symptoms, or rash with accompanying fever. Mutations in *MEFV* have been identified in approximately 5% of patients with European ancestry in the United States with higher prevalence in the Middle East.³ Of these populations, only 1% to 2% of patients develop clinical symptoms suggesting incomplete penetrance and/or genetic or environmental cofactors.^{3,4} In both PFAPA and FMF, treatment with colchicine is effective, likely through disruption in microtubule trafficking of inflammasomerelated proteins, thereby, reducing overall inflammasome production.^{5,6}

Patient 1






FIGURE 1. Pedigrees for patient 1 and patient 2.

A recent study reported worsening FMF symptoms after acute COVID-19 illness in 33% of patients with FMF,⁷ perhaps through additive inflammasome dysregulation, which can occur both in patients with FMF⁸ and in patients with acute COVID infection.⁹ Given the potential for effective therapy, clinicians should obtain a thorough fever history and consider genetic testing for autoinflammatory diseases in children experiencing post-COVID recurrent fevers.

- ^bDepartment of Pediatrics, Division of Allergy and Immunology, National Jewish Health, Denver, Colo
- No funding has been received for this study.
- Conflicts of interest: The authors declare that they have no relevant conflicts of interest.
- Received for publication January 24, 2023; revised February 24, 2023; accepted for publication February 28, 2023.

Available online March 9, 2023.

Corresponding author: Nathan Rabinovitch, MD, MPH, Department of Pediatrics, Division of Allergy and Immunology, National Jewish Health, 1400 Jackson St. K801, Denver, CO 80206. E-mail: rabinovitchn@njhealth.org.

2213-2198

© 2023 American Academy of Allergy, Asthma & Immunology https://doi.org/10.1016/j.jaip.2023.02.036

REFERENCES

- Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, Perelman C, Sepulveda R, Rebolledo PA, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep 2022;12:9950.
- Salehzadeh F, Vahedi M, Hosseini-Asl S, Jahangiri S, Habibzadeh S, Hosseini-Khotbesara M. PFAPA and 12 Common MEFV gene mutations our clinical experience. Iran J Pediatr 2014;24:64-8.
- Fujikura K. Global epidemiology of familial Mediterranean fever mutations using population exome sequences. Mol Genet Genomic Med 2015;3:272-82.
- Mikula M, Buller A, Sun W, Strom CM. Prevalence of known mutations in the familial Mediterranean fever gene (MEFV) in various carrier screening populations. Genet Med 2008;10:349-52.
- Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974;291:932-4.
- Welzel T, Ellinghaus M, Wildermuth AL, Deschner N, Benseler SM, Kuemmerle-Deschner JB. Colchicine effectiveness and safety in periodic fever, aphthous stomatitis, pharyngitis, and adenitis. Front Pediatr 2021;9:759664.
- Guler AA, Inel TY, Kasifoglu T, Coskun C, Karadeniz H, Yildirim D, et al. COVID-19 in familial Mediterranean fever: clinical course and complications related to primary disease. Mod Rheumatol. Published online July 21, 2022. https://doi.org/10.1093/mr/roac074.
- de Torre-Minguela C, Mesa Del Castillo P, Pelegrín P. The NLRP3 and Pyrin inflammasomes: implications in the pathophysiology of autoinflammatory diseases. Front Immunol 2017;8:43.
- Pan P, Shen M, Yu Z, Ge W, Chen K, Tian M, et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat Commun 2021;12:4664.

^aDepartment of Medicine, Division of Allergy and Immunology, National Jewish Health, Denver, Colo